Companies › Bio-Path Holdings
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BP1001 Liposomal Grb-2 antisense oligonucleotide (GRB2 mRNA inhibitor) | GRB2 | Phase 2 | Acute Myeloid Leukemia (AML) | Dec 2027 |
| BP1002 Bcl-2 antisense oligodeoxynucleotide | BCL2 | Phase 1 | Mantle Cell Lymphoma; Acute Myeloid Leukemia, in Relapse | Mar 2027 |
| BP1001-A Liposomal Grb2 antisense oligonucleotide | GRB2 | Phase 1 | Solid Tumor, Adult | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04072458 | BP1002 | Phase 1 | Mantle Cell Lymphoma | Oncology | Apr 2025 |
| NCT05190471 | BP1002 | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oncology | Mar 2027 |
| NCT04196257 | BP1001-A | Phase 1 | Solid Tumor, Adult | Oncology | Jul 2027 |
| NCT02781883 | BP1001 | Phase 2 | Acute Myeloid Leukemia (AML) | Oncology | Dec 2027 |
Cash of $0m on 2026-03-31; operating cash outflow about $0m a year; runway about 1 months at that burn, to Apr 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Neonc Technologies Lantern Pharma Imbioray (Hangzhou) Biomedicine Inhibrx Biosciences Immuneering
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.